Trial Profile
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Onalespib (Primary) ; Abiraterone acetate; Prednisolone; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Astex Pharmaceuticals
- 12 May 2019 Results published in the Clinical Cancer Research
- 09 Mar 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 13 Jan 2015 Planned End Date changed from 31 Jan 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.